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Abstract
A key goal of pharmacogenetics — the use of genetic variation to elucidate inter-individual variation
in drug treatment response — is to aid the development of predictive genetic tests that could maximize
drug efficacy and minimize drug toxicity. The completion of the Human Genome Project and the
associated HapMap Project, together with advances in technologies for investigating genetic
variation, have greatly advanced the potential to develop such tests; however, many challenges
remain. With the aim of helping to address some of these challenges, this article discusses the steps
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that are involved in the development of predictive tests for drug treatment response based on genetic
variation, and factors that influence the development and performance of these tests.
The clinical premise of pharmacogenetics is based on more accurate, and hence more useful,
predictive medicine. The underlying assumption is that a person's genotype will determine
whether they will respond to, or have toxicity from, a given medication. It appears that genetic
variation, along with clinical and behavioural information, will be useful in this regard.
However, the relative importance of genetic versus clinical factors over the broad range of
medications currently in clinical use is yet to be determined.
Existing pharmacogenetic tests can be broadly divided into two categories: identifying
responders or non-responders to a given drug and identifying those individuals at risk of serious
adverse events.
Pharmacogenetics has benefited from the rapid advances associated with the Human Genome
Project and its derivative the HapMap Project (see Further information). In 2000, an overall
map of the human genome was released1,2, and in the past 5 years, the HapMap Project has
catalogued human genetic variation, which is defined as “genetic variation with the allele
frequency of more than 10%”, in three ethnic groups: Caucasians, Africans and Asians (both
Han Chinese and Japanese). This has allowed researchers to use linkage disequilibrium to find
genetic variation related to common complex traits, such as drug treatment response3. As can
be seen from FIG. 1, there are two broad types of variation in the human genome: common
genetic variation and rare genetic variation. Common genetic variation occurs with an allele
frequency of more than 1%, and tends to be evolutionary older and to affect gene regulatory
function4. Rare genetic variation occurs with an allele frequency of less than 1%, and tends to
arise more recently in human evolution and, when present at non-synonymous sites in coding
regions, it is more likely to alter protein structure4. The relationship of these population genetic
principles to pharmacokinetic and pharmacodynamic responses are unknown at present but
worthy of further investigation.
With the rapid expansion of knowledge and tools that enable the study of complex human
genetic traits, and with genome-wide data rapidly accumulating, now is an opportune time to
focus on the factors affecting the development of pharmacogenetic tests. In this article, we
discuss key factors in the development of pharmacogenetic tests. These include those that
influence the rationale for developing such tests for particular purposes, those that affect test
performance in general, and those relating to test regulation and uptake by clinicians. We also
propose an approach to predict treatment responses in complex clinical drug-response
phenotypes. We are focusing this manuscript on actual genetic variation and its influence on
drug treatment response, recognizing that transcriptomic and proteomic approaches to predict
drug response are also possible and desirable (for a recent review see Ross et al.5). Our focus
is also on the identification and application of knowledge of the influence of genetic variation
on the effects of approved drugs, rather than on the application of pharmacogenetic tests in the
development of investigational drugs, although many of the points highlighted could also be
relevant in this case. For a discussion of this topic, see Jain6.
Although the use of pharmacogenetic testing to guide therapy is a new approach, the use of
laboratory testing to guide therapy is not novel. For instance, serum creatinine levels are
routinely used to guide drug dosage, and antibiotic sensitivity testing is used to select drugs
that work for specific conditions. Other examples include following the international
normalized ratio after warfarin treatment, and monitoring the concentrations of some drugs
such as phenytoin, lithium and gentamicin to guide dose selection and the timing of dosing.
Pharmacogenetic testing can be seen as an addition to the treatment algorithm that should not
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be difficult to implement, in theory. There are various issues including education and cost that
could have an important impact in this respect in practice, as discussed later in this article.
Currently, pharmacogenetic tests are used for assigning the dose of 6-mercaptopurine based
on the thiopurine S-methyltransferase (TPMT) genotype7-9; to decide whether or not to use
codeine or tamoxifen based on the cytochrome P450 family 2, subfamily D, polypeptide 6
(CYP2D6) genotype10; and to design optimal treatment regimens for colon cancer using
irinotecan with the UDP glucuronosyltransferase 1 family, polypep-tide A1 (UGT1A1)
genotype. In addition, pharmacogenetic tests have recently been developed to define warfarin
dosage more accurately on the basis of vitamin K epoxide reductase complex, subunit 1
(VKORC1) and CYP2C9 genotypes (TABLE 1).
Factors affecting test development
The clinical consequences of pharmacogenetic tests differ substantially depending on the
setting. The utility of a clinical test is dependent on the clinical options available. If there are
no clinical options then the test only provides a warning of potential events to come. If there
are clinical options then the clinician can err on the side of either false positives or false
negatives depending on the clinical risk of making an erroneous decision. The clinical context,
the availability of other tests in the clinical environment, as well as the frequency and severity
of the drug-response phenotype, all have important roles in determining how useful, and widely
applied, a given predictive test will be. This therefore underlies whether a test for a particular
drug response should be developed in the first place. For instance, the use of the UGT1A1 test
to prevent irinotecan toxicity represents a different clinical context compared with the use of
the VKORC1 test to predict optimal warfarin dosage.
Just as there are different clinical models for drug treatment response, there are different genetic
models as well. Some drug effects behave in a Mendelian fashion and are due to a single coding
variant in a single gene. An example of this would be the common genetic variant in the CyP2C9
enzyme — a C to T nucleotide substitution at codon 430, which results in a change from
arginine to cysteine at amino-acid 144 (see Further information). This mutation in CYP2C9
causes a decrease in the metabolism of warfarin and thus, an increased risk of bleeding
compared with a person without this variant receiving the same dose11. In other cases, the drug
effect might be due to multiple single nucleotide polymorphisms (SNPs), some coding and
some regulatory, in a single gene. An example of this would be variants in the β2 adrenergic
receptor (ADRB2), which influences the response to inhaled short-acting β-agonists12. These
multiple variants could be combined to create a haplotype or combination of variants.
In contrast to these single gene effects, many drug treatment response phenotypes are complex,
produced by multiple coding and regulatory variants in multiple genes that often interact in a
signalling pathway. In these cases, each variant could contribute to the variance in the
phenotype and there is no clear model of genetic inheritance. Genetic factors that influence
whether a drug treatment response is complex include mode of inheritance (recessive versus
dominant or additive); pleiotropy; incomplete penetrance; and epistasis, due to gene–
environment interactions and environmental phenocopies. All of these factors contribute to the
complexity of the response phenotypes. As of yet we have no good examples of such complex
drug treatment response tests.
The clinical phenotype itself may be difficult and elusive. In some cases the definition of a
responder or a non-responder is clear, whereas in others it can be arbitrary. As shown in FIG.
2, the response to inhaled corticosteroids, as measured by the forced expiratory volume in 1
second (FEV1), can be considered a linear relationship. One might also categorize the negatives
or non-responders (the bottom 30% of the distribution), as individuals who have a non-
response, or a clinically poor response phenotype, to inhaled corticosteroids as characterized
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by FEV1. This example is emblematic of a certain class of genetic tests in which a continuous
phenotype, here FEV1, is dichotomized to create a binary variable with a discrete response. In
many clinical situations, the response might involve a biomarker (for example, the cholesterol
level in response to a statin medication) rather than a specific disease phenotype. linear
modelling can also be used to model continuous drug-response phenotypes such as those
already noted. Thus, there are multiple models for the separation of drug-response phenotypes.
However, if the purpose of the test is to separate groups of patients according to response
phenotypes (for example, responders or nonresponders) then the separation of these two groups
should be made using well-recognized clinical response measures when they are available. For
instance, we know that the degree of change in bone density affects the risk of bone fracture,
and that the magnitude of change in low-density lipoprotein or blood pressure levels is
associated with cardiovascular risk, and so these can be assessed continuously or as
dichotomous phenotypes.
It is important to recognize that while pharmacogenetic tests are intended to be applied to
individual patients, their predictive power is based on population samples of patients and their
drug responses. This means that pharmacogenetic testing can be used for predictive medicine
but not for truly personalized medicine, as the testing is based on how a group of individuals
with the same polymorphisms and the same drug-response phenotype would behave in a similar
clinical situation.
Because pharmacogenetic testing can be predictive of treatment outcome, its use differs from
other clinical tests. Clinical tests (such as serum drug levels) are less specifically diagnostic of
disease and drug response, and often require integration with other clinical variables to have
any clinical utility. However, similar to other clinical tests (such as serum creatinine, serum
cholesterol, serum drug concentrations of gentamicin or phenytoin, or fasting glucose level),
the predictive capabilities of pharmacogenetic testing are population based.
The expectation is that genetics will allow more precise prediction than clinical variables alone.
This is partly because of the stability of DNA in the laboratory compared with other biological
samples such as RNA or protein. This is in addition to the fact that germline DNA does not
change in an individual's lifetime and the robust nature of genetic tests, which provide clear
data on DNA sequence as opposed to a measurement of a linear variable such as the density
of an RNA species on an array or microchip, or the presence of a protein on a Western blot.
However, more important than these biochemical properties, the accuracy of a given prediction
depends on whether the full set of relevant genes (and their genetic variants) that are related
to the phenotype of interest has been delineated. Furthermore, accuracy will also depend on
clinical and environmental factors that influence the drug response, and on the genetic and
predictive models that relate genetic factors to drug response. It remains unknown whether
transcriptomic, or proteomic predictive tests are superior to genetic tests. Measurement of
protein levels will probably provide the most specific model for drug treatment response, but
few comparisons between these approaches and a genetic one are available.
Predictive genetic tests could also be of value in the drug development process, rescuing drugs
that would not pass approval by the US Food and Drug Administration (FDA) in Phase III
trials because of the susceptibility of a subset of patients to an adverse event. Tests of high
predictive accuracy that are able to identify patients who are susceptible to serious adverse
events, or to treatment non-response, could help salvage drug approval. An example of this is
the use of major histocompatibility complex, class I, B (HlA-B)*5701 testing in patients with
HIv who are receiving abacavir13.
Finally, drug safety and drug efficacy are central to developing clinical pharmacogenetic tests.
In general, drugs are approved because they have been shown in Phase III clinical trials to
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benefit individuals treated with the medication relative to placebo, or relative to the standard
of care. However, there are still individuals at the extreme of the drug-response distribution
who do not respond, as well as some individuals who have adverse responses. Although adverse
responses might be rare, and might only come to light in the post-marketing surveillance of a
medication (or when Phase III trials are initiated), non-responders are often ignored unless they
represent a significant proportion of the patient population. Pharmacogenetic testing can be
used to identify both those who are unlikely to respond and those that are most likely to have
an adverse reaction, thus maximizing the clinical utility of a drug.
Factors influencing test performance
Although many technical and logistical hurdles must be overcome before a test can be
implemented in a clinical laboratory, several additional factors can also influence the clinical
impact of a pharmacogenetic test. Many of these factors cannot be controlled or manipulated,
but are clinically important. Among the genetic factors that influence test performance are
allele frequency, linkage disequilibrium, epistasis and the number of functional gene variants.
Allele frequency has important practical implications for pharmacogenetic testing. variants
with a low allele frequency might have substantial influence on toxicity risk or effectiveness,
but the small number of patients with the genotype of interest could make it difficult to establish
the clinical and/ or economic value of prospective testing. An example is the use of
CYP2C19 genotype for predicting clinical resistance to proton pump inhibitors in gastric ulcer
therapy. The low frequency of a homozygous variant genotype in European-derived white
populations is largely responsible for the low uptake in CYP2C19 testing in the Western world.
The opposite is true in East Asia where the at-risk genotype occurs in ∼20% of patients14,
15.
Linkage disequilibrium also has an influence on pharmacogenetic testing. The power of linkage
disequilibrium for discovering genes of interest in the entire genome is clear, but problematic.
The variant that is associated with the clinical phenotype of interest is not necessarily causative.
This was seen with the discovery of VKORC1 haplotypes, which are associated with greater
sensitivity to the anticoagulant effects of warfarin16. It now appears that the original predictive
SNPs are actually SNPs in linkage disequilibrium for a promoter region SNP that alters
VKORC1 transcription and thereby warfarin dose requirements.
Linkage disequilibrium occurs for most of the world's population, but for many genes there
are substantial differences in the degree of linkage disequilibrium observed across populations.
Furthermore, there are often multiple genotype explanations for an altered phenotype, making
linkage disequilibrium inadequate to detect the causative variants. This is the case for TPMT
and thiopurine sensitivity, for which 85−90% of at-risk patients will be detected using only
three non-synonymous SNPs, but over 20 causative variants have been observed across the
world17,18. Allele heterogeneity, the concept that all causative SNPs do not produce identical
phenotypes, is also important in the interpretation of pharmacogenetic tests. For example,
genetic variants in CYP2D6 may range from variants that are non-functional, giving rise to
poor metabolizers, to variants that are intermediate in function.
Epistasis or gene–gene interactions may also affect the outcome of pharmacogenetic tests.
Although looking at several genes together makes for complex analysis, by analysing one gene
at a time we might miss a clinically important interaction between variants within a gene or
between genes.
Recently, there has been evidence for the need to consider pharmacogenetics in a quantitative
rather than qualitative manner. A hallmark of cancer cells is aneuploidy (an abnormal number
of chromosomes) primarily at the level of large segments of genomic loss or amplification.
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The altered regions often contain genes of biological importance, sparing genes whose function
might not be directly related to tumour biology but may nevertheless have some
pharmacogenetic function19,20. However, recent studies in leukaemia have demonstrated that
the interaction between gene polymorphism and gene amplification can have a quantitative
functional impact21. A patient with a TPMT heterozygous genotype (for example, G/A) and
three copies of TPMT in their leukaemia blast cells actually has a G/G/A or G/A/A genotype,
which affects the enzyme's activity. This phenomenon cannot be readily detected by the
genotyping technologies that are used in clinical laboratories, thus illustrating the need for
diagnostic approaches that provide the necessary information to integrate such data into
practice22. A similar distinction has also been observed in the context of solid organ
transplantation, in which the genotype of the donor organ was found to be more predictive of
drug-associated nephrotoxicity rather than the recipient's genome23.
Clinical or biological factors that influence the performance of a pharmacogenetic test are not
necessarily related to genetic variation. Indeed, drug–drug and nutrient–drug interactions are
important sources of discrepancy between genotype and phenotype. For example, the
CYP2D6 genotype of patients with breast cancer appears to influence the metabolism of
tamoxifen24. Nutritional factors, such as folate, have also influenced pharmacogenetic tests
for drugs such as warfarin. In the case of warfarin, folate intake also influences the predictive
value of genetic tests for VKORC1 as a predictor of anticoagulant response25. These findings
indicate that, in addition to clinical information, pharmacogenetic tests will provide added
information about the pharmacological milieu of a patient. However, these tests will not replace
good clinical management of a patient's treatment regimen, and, in order to be clinically
valuable in treatment decisions, they must be interpreted by professionals that are capable of
taking the clinical context into account.
Expertise in the interpretation of pharmacogenetic tests is particularly challenging. By
definition, a pharmacogenetic test involves a therapy and the condition it is designed to treat,
and it cannot be of value if it is considered in an isolated manner. The test should predict a
clinically meaningful difference in drug effect or it will have little value, even if its analytical
specifications are robust. Interpretation of a clinically meaningful difference inevitably
depends on both the disease and the context, and this decision is best made by clinical experts.
When pharmacogenetic tests have been used in the treatment of osteoporosis, endocrinologists
and rheumatologists have defined the degree of change in biomarkers for bone strength that
affect the actual risk of bone fracture. In some areas of medicine — such as the treatment of
hypertension, hyperlipidaemia, osteoporosis, depression or some cancers — clearly defined
clinically relevant changes due to drug therapy have been defined by consensus panels, and
these should be used in the interpretation of tests aimed at improving therapy. That said, in
many areas of pharmacotherapy, such clear guidelines do not exist and the response to treatment
remains frustratingly variable. In these cases, we must await the development of meaningful
biomarkers of treatment response before the value of some tests can be assessed.
Physicians remain the most important medical decision makers and their involvement in the
development and use of pharmacogenetic tests is crucial. However, given that
pharmacogenetics is a rapidly evolving field, ideally, a multidisciplinary team approach to
pharmacogenetic test interpretation, involving physicians, pharmacists, geneticists, clinical
chemists and nurses, should evolve. Without better physician education, there is a real danger
that pharmacogenetic tests will be used in ways that do not optimize health care, or may actually
harm patients by resulting in the use of the wrong drug at the wrong time in the wrong patient.
Finally, all clinical tests, including genetic tests, are judged by their intrinsic test characteristics;
that is, their sensitivity, specificity, reproducibility and precision (BOX 1).
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Factors influencing test approval/uptake
Most clinical tests have been developed and released into clinical practice with limited attention
to their characteristics and performance. Although tests for research purposes require no
approval, any laboratory test that will be used for patient care, including any pharmacogenetic
test, must comply with the Clinical laboratory Improvement Amendment of the United States
or comply with the In Vitro Diagnostic Directive of the European Union; that is, the test is able
to pass sufficient laboratory standards to receive a Committee Europe mark. Equivalent
standards exist in Japan and other Asian countries.
Box 1| Clinical test characteristics
Sensitivity and specificity
Sensitivity is defined as the number of subjects in the test that test positive and have a
positive drug response divided by the total number of subjects who have a positive drug
response. Specificity is defined as the number of subjects in the test that test negative and
have no drug response divided by the total number of subjects who have no drug
response31. Sensitivity and specificity are intrinsic characteristics of a test. However, a
test's predictive value depends not only on sensitivity and specificity, but also on response
prevalence; that is, how well the drug works in how many people. A high response
prevalence is associated with more false positives. A low response prevalence is associated
with more false negatives. One of the ways of quantifying the clinical performance of a
given predictive test is to construct a receiver operating characteristic (ROC) curve31.
Reproducibility and precision
Additional concepts that are crucial to interpreting diagnostic or prognostic tests are
reproducibility and precision. Reproducibility is simply the capability of a test to give the
same results repeatedly in the same individuals. Characteristics that can influence
reproducibility include the testing method (for example, sequencing of both DNA strands
(the gold standard) or genotyping by Taqman or by oligonucleotide array), and the quality
of the DNA sample. A test should be robust, that is, it should function well in all types of
clinical situations. It should also be highly reproducible when tested on individuals under
standard conditions. In the case of tests for genetic variants that are relevant to therapeutic
response, the stability of DNA lends itself to clear and reproducible results, but every test
must be validated in the clinical environment for which it is intended.
These standards include reproducibility and precision — parameters that validate that the test
actually measures what it is intended to measure. Tests that are not highly reproducible and
precise have little chance of being clinically useful. It is of note that the US FDA also has a
process for approving clinical tests, including genetic tests, and has recently established
guidelines for this process that include the demonstration of clinical utility, a requirement that
is not imposed by the regulatory agencies in other countries26. In addition, the FDA requires
studies that determine test performance, describe the rationale for the cut-off used for the test,
precision and reproducibility data, analytic specificity data (indicating no interference or cross-
reactivity), as well as details about the analysis and conditions of the test27. Although FDA
approval is not currently a requirement for all genetic tests, this regulatory question remains
open. The FDA has approved a small number of pharmacogenetic tests, including the
Amplichip CyP450 Test (Roche), which analyses CYP2D6 and CYP2C19, and the Invader
UGT1A1 Molecular Assay (Third Wave Technologies/Genzyme), which is used in guiding
irinotecan dosage. The FDA-approved labels for azathioprine, 6-mercaptopurine, atomoxetine,
irinotecan and warfarin all include references to the availability of a pharmacogenetic test that
will aid health-care professionals make therapeutic decisions.
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Medical science has already provided an array of clinical variables with which to predict
response to drug therapy. Physicians use these routinely, and they are well integrated into the
practice of medicine. Thus, the clinical value of any new test depends, in part, on what is
currently available and routinely used. For example, the effectiveness of statins is usually
followed by the measurement of cholesterol and lipoprotein subfractions. In the cancer field,
tumour stage and grade are used as measures of disease severity, and oncologists routinely use
them to predict how patients will respond to treatment. In breast cancer, for example, oestrogen
and progesterone receptor status, HER2 status, and in some patients a 21-gene expression panel
can be measured, which, together with the tumour grade and stage are used to determine the
most appropriate therapy28. A woman with an oestrogen receptor-positive tumour is most
likely to receive an endocrine treatment, such as tamoxifen or an aromatase inhibitor, to target
that receptor.
In the case of antihypertensive agents, their effectiveness is monitored by the measurement of
blood pressure, and changes in dose or drug are frequently made as a result. Similarly, the
extent of β-blockade is assessed by measurement of the heart rate; the adverse effects from
dopaminergic blockade by watching for extrapyramidal signs; and the adverse effects of
anxiolytic therapy by monitoring patients for excessive sedation or memory loss. For a new
pharmacogenetic test to be useful in these situations, it should not only be robust in a clinical
environment (involving real patients taking multiple drugs and with a range of disease severity),
but it should also be more predictive than current approaches. The field of breast-cancer
treatment is particularly rich in genomic predictive tests and similar tests are becoming
available in the treatment of other cancers, in which both the somatic DNA, present in the
tumour itself, and the patient's germline DNA are used29. Both may be useful, and the testing
characteristics and performance for each should be similar.
An approach to prediction
Pharmacogenetics is still struggling to identify clinically meaningful treatment responses that
can be predicted by genetic testing. Here, we describe one of the approaches that is being used
by investigators in the Pharmacogenetics Research Network (PGRN) to predict treatment
response in complex clinical drug-response phenotypes (determined by multiple clinical
variables and multiple genes that interact in a network or pathway) (FIG. 3). Currently, this
approach is being used by the Pharmacogenetics of Asthma Treatment Group of the PGRN to
develop genetic tests that predict asthma exacerbations, response to inhaled corticosteroids and
response to inhaled β-agonists.
The first step is to use linkage dis-equilibrium within genes to identify a set of genes that
replicate an association with a drug-response phenotype across several clinical trials in a single
ethnic group. The critical question at this stage is what constitutes adequate sample sizes for
prediction. This is dependent on the SNP set that is being used for prediction: is it a subset of
a whole genome (300,000−1,000,000,000 SNPs) or just a subset of SNPs in candidate genes?
The problem of too many predictors for a small sample of cases and controls is well known in
bioinformatics: the developed prediction model is not generalizable and hence not reproducible
in a second population. Initial predictive models for pharmacogenetics were built with as few
as 200 cases and controls, with candidate gene sets of several thousand SNPs. Now, they are
utilizing a similar set of cases and between 500,000−1,000,000 SNPs.
The bioinformatics approach used to investigate the epistatic interactions between these
predictive gene sets relies on software that utilizes Bayesian networks, a form of statistical
modelling, that takes into account the dependencies between the outcome (in this case drug
treatment response as a dichotomous variable, that is, responder/ non-responder) and multiple
SNPs. The software (Bayes’ Discoverer) evaluates each individual SNP as a potential predictor
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node of an epistatic network based on the ratio of two probabilities (Bayes factors) that
quantitatively assess the marginal contribution of the SNPs to the overall predictive
model30. The resulting network models seem to have reasonable predictive power based on
the receiver operating characteristic (ROC) curve area and have been shown to replicate across
trials of one ethnic group.
Box 2 | Ethical issues
Given the recent increased focus on the privacy of health-care data, and the high likelihood
that all individuals in the population harbour susceptibility alleles for some
pharmacogenetic phenotype, as well as the goals of genetic non-discrimination, the
possibility of discrimination on the basis of pharmacogenetic test results seems limited.
Despite the limited possibility of stigmatization based on disease susceptibility, there
remains concern about the differential application of these tests in specific ethnic groups.
The possibility that results from a predictive test will differ between racial and ethnic groups
is a concern. The genetic context here refers explicitly to varying linkage disequilibrium
patterns and differing allele frequencies based on the evolutionary history of different
populations. This may be an important concern particularly in the first generation of
predictive tests, which will primarily be based on linkage disequilibrium rather than on
functional variation. This could lead to varying predictive performance in different racial
and ethnic groups. In the future development and use of pharmacogenetic tests, it will be
important that all communities become active participants and that patients, physicians and
health-care providers are made aware of their existence. Ancestral informative markers,
that is, genetic variation that is associated with human populations based on their
evolutionary history, will aid in understanding linkage disequilibrium patterns among racial
and ethnic groups.
Developing the initial model is done with linkage disequilibrium tagging SNPs, but it is
unlikely that these will be generalizable to other racial groups. Although currently untested, it
stands to reason that generalizability can be achieved with linkage disequilibrium tagging SNPs
if these SNPs are known for other ethnic groups besides the group that was initially chosen.
Thanks to data from the HapMap Project, linkage disequilibrium tagging SNPs for the whole
genome have been identified for several racial groups. However, some addition and substitution
may need to be done to use a linkage disequilibrium tagging approach for epistatic prediction
before all functional variants are defined.
The second step is to try to replicate the epistatic interaction model in an independent clinical
trial population and explain a significant portion of the area under the ROC curve. Once
replication is achieved, then the third step is to define the functional variants in the genes
identified using the Bayesian network modelling approach as described above. In this step the
functional variants rather than the variants based on linkage disequilibrium are used in an
iterative fashion to find the epistatic interactions between the functional variants leading to the
clinical phenotype. Then, one could build a new model based on these functional variants as
predictors of the clinical phenotype. It is likely that this will have broader generalizability than
a model built using linkage disequilibrium SNPs. After the model is validated, either in an
observational study or in a clinical trial, these variants can be put on a chip to determine whether
the test is adequately sensitive and specific for predicting clinical outcomes in a variety of
clinical populations.
Alternative or complimentary approaches to the one outlined here would include use of gene-
expression signatures to model response, and using linear or logistic regression to focus on
main effects rather than epistasis. It is likely that all of these models will be used by different
groups of investigators.
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It is also important to develop interpretation guidelines for the test, especially regarding how
it might influence drug-prescribing patterns. The guidelines would describe either a change in
dose or selection of drug types to use as a result of the test. Finally, it would be desirable to
validate such a predictive model through testing in the general population, as prospective
randomized genotype-guided dosing trials will take too long and be too costly to perform
routinely and thus, validation is likely to be performed in observational cohorts.
Conclusions
Expectations are high regarding the application of the results of the Human Genome Project
to clinical medicine; one of the most direct applications of the data will be in the area of
prediction, including pharmacogenetics. With the recent enactment of the Genetic Information
Nondiscrimination Act in the United States this year, discrimination concerns would appear
to be less of an issue, although ethical concerns in genetic testing are still relevant (BOX 2).
Questions remain as to the realistic time frame within which to expect the development of
pharmacogenetic tests and how the field will move forward. The trend is to use ever larger sets
of SNPs, iterative multivariate modelling and replication with ROC area as the best approach
to evaluate the results. We propose that developmentally useful tests in pharmacogenetics for
complex traits will become increasingly available at an exponential rate over the next 10 years.
Existing clinical pharmacogenetic tests and prototypes have already been developed, or are
under development by research groups within the PGRN (see Further information). The next
tests are likely to take advantage of whole-genome data and to include multiple gene variants.
It will take time to integrate these emerging tests into daily practice given the need for iterative
development, validation and ultimately FDA approval. Even currently available tests approved
by the FDA are not used routinely in all clinical practices and many physicians feel that they
can predict drug response just as well with their clinical experience as they can with a genetic
test. However, within 10 years, clinically useful predictive tests with reasonable sensitivity and
specificity are likely to be available for many drug-response phenotypes. It is likely that these
will cost under US$100 per test and that they will be interpreted by trained clinicians. Despite
this, these tests will not substitute for good clinical judgment and will not replace careful
thought by the practitioner about the dose and choice of drug. Predictive medicine will be one
of the first major applications of the human genome to clinical medicine, and more precise
prediction of drug response will improve drug prescribing for all patients.
Glossary
Environmental phenocopy
A clinical case of a complex trait due solely to environmental factors.
Epistasis
The interaction or interdependence of two or more genes.
Incomplete penetrance
Occurs when less than 100% of a population with an identical mutant genotype display the
associated phenotype.
Linkage disequilibrium
The nonrandom association of alleles in the genome.
Mode of inheritance
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Dominant mode of inheritance occurs when only one copy of the allele is necessary to
produce the phenotype. Recessive mode of inheritance occurs when both copies of the allele
are necessary to produce the phenotype.
Pleiotropy
A single mutation that has more than one biological effect or phenotype.
Receiver operating characteristic (ROC) curve
A curve that plots I-sensitivity on the y axis and specificity on the x axis. The area under
this curve is a measure of test performance.
Severe adverse event
An event that occurs less than 1 in 10,000 administrations of the medication and is life
threatening.
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Figure 1. Common genetic variation and rare genetic variation with allele frequencies
Genetic variants that occur with an allele frequency of less than 1% are more likely, by
definition, to be rare. They are more likely to be non-synonymous coding variants, which will
influence pharmacokinetic responses, and to be under natural selection. Variants that occur
with an allele frequency of more than 1% are more likely, by definition, to be common. They
are more likely to influence gene regulation, which is important in determining
pharmacodynamic responses, and are unlikely to be under significant natural selection
pressure. SNP, single nucleotide polymorphism.
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Figure 2. response to inhaled corticosteroids, as measured by FEV1
This shows the distribution of improvement in forced expiratory volume in 1 second (FEV1),
a measure of lung function, in response to inhaled corticosteroids taken over a 6−8 week period.
The x axis is change in FEV1 and the y axis is the number of subjects having that level of
change in FEV1 in three different studies: an adult clinical trial (Adult study), the childhood
asthma management program (CAMP) and one of the Asthma Clinical Research Network
(ACRN) clinical trials. The histogram shows a wide range of response between individuals to
the inhaled corticosteroid medication. This figure is modified with permission from REF. 32
© (2004) Oxford University Press.
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Figure 3. Proposed methodology for developing pharmacogenetic predictive tests
This flow diagram describes the steps to take in the development of a hypothetical predictive
pharmacogenetic test. The cut-off of 10% in step two is arbitrary. The methodology for
combining variants in step four could be any multivariate approach not just Bayesian networks.
Validation (step six) will probably occur in samples from the general population rather than in
randomized controlled trials.
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Table 1
Examples of recently approved or emerging pharmacogenetic tests
Gene Drug Consequence
KIT mutations* Imatinib mesylate‡ Altered survival
TPMT Mercaptopurine and azathioprine* Neutropaenia
UGT1A1* Irinotecan‡ Neutropaenia
CYP2C9/VKORC1 Warfarin International normalized ratio
CYP2D6* 5-HT3 receptor antagonists Inadequate anti-emetic control
Antidepressants Inadequate benefit
ADHD drugs Inadequate benefit
Codeine derivatives* Inadequate benefit
*
US Food and Drug Administration (FDA)-approved device.
‡
FDA package insert information. 5-HT3, 5-hydroxytryptamine (serotonin) 3; ADHD, attention-deficit/hyperactivity disorder; CYP, cytochrome P450;
TPMT, thiopurine S-methyltransferase; UGT1A1, UDP glucuronosyltransferase 1 family, polypeptide A1; VKORC1, vitamin K epoxide reductase
complex, subunit 1.
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